Skip Ribbon Commands
Skip to main content

Multiple Myeloma Medicare Study

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   |   Studies   |   Clinical Trials   |   Medicare Clinical Trials   |   Multiple Myeloma Medicare Study
  • Print
  • Share

Multiple Myeloma Medicare Study

Patients with Medicare are eligible for coverage of HCT for multiple myeloma if they participate in a CED clinical trial.
Study Title: Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma (17-CMS-MM)
Clinical trial number: NCT03127761
This study is a sub-study under the CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies, and Marrow Toxic Injuries NCT01166009
Opened: July 25, 2017
Study Objectives:
  • The primary outcome is to compare five-year OS probabilities between the alloHCT cohort and an age and disease risk matched cohort of autoHCT patients. OS is calculated for all patients from the date of transplant until death from any cause.
  • To provide a mechanism to Medicare Beneficiaries with multiple myeloma for claims coverage for allogeneic HCT. 
  • To provide data requested by Medicare under its CED to make payment on claims for HCT using the existing research observational database of the CIBMTR

Participating Transplant Centers are required to:

1. Create a CRID in FormsNet following standard CIBMTR process. 
2. Complete Form 2554 (CMS Registration Form, an on-demand form) in
a. Select disease option for Multiple Myeloma
3. Complete Form 2400 (Pre-TED). Select RCI BMT as the study sponsor, and then
    select 17-CMS-MM from the list of studies.
4. Complete Form 2402 indicating the disease is Multiple Myeloma.
a. Eligible classifications include
i. MM-IgG
ii. MM-IgA
iii. MM-IgD
iv. MM-IgE
v. MM-IgM (not Waldenstrom)
vi. MM-light chain only
vii. MM-non secretory
5. Submission of Comprehensive Report Forms will be required for all registered  
    study patients.
Patient Eligibility:
  • Medicare beneficiaries
  • Have Stage II or III multiple myeloma 
  • Are eligible to receive an alloHCT from any suitable allogeneic donor (as determined by the transplant center) including umbilical cord blood
  • Being treated in a US transplant center
  • Provide informed consent to participate in the study

Consent Forms:

This study uses the existing research observational database of the CIBMTR to collect data requested by CMS as part of its payment policy. Patients enrolled on CIBMTR studies for indications under CED will sign a separate CMS consent form under the Research Database Protocol for participation in a CMS CED-approved study. These patients will be invited to participate in both the CMS CED study and the Research Database protocol. Patient participation in the CMS CED study is not dependent on their participation in the Research Database Protocol. Additional protocol or consent forms are not required for this study.

The Research Database protocol, CMS consent form, and CIBMTR/NMDP IRB approvals, can be found on the Observational Database and Protocol and Consent Forms web page.

Study Contacts:

For clinical research questions contact:

Beginning May 22, 2019, all questions from centers must be submitted via Center Support in the ServiceNow application. Please include the study ID# 17-CMS-MM in your ticket.

For more information about Service Now

For Medicare claims questions contact:

NMDP/Be The Match Payer Policy team,

For more information about Medicare Coding and Billing

Study Reference Materials:

Study Plan: 17-CMS-MM


Last Updated: 5/25/2021 2:46 PM